P49 MAGELLAN-1, PART 2: glecaprevir and pibrentasvir for 12 or 16 weeks in patients with chronic HCV genotype 1 or 4 and prior direct-acting antiviral treatment failure

• Fred Poordad,
• Stanislas Pol,
• Armen Asatryan,
• Maria Buti,
• David Shaw,
• Christophe Hézode,
• Franco Felizarta,
• Robert W. Reindollar,
• Stuart C. Gordon,
• Stephen Pianko,
• Michael W. Fried,
• David E. Bernstein,
• Joel Gallant,
• Chih-Wei Lin,
• Yang Lei,
• Teresa I. Ng,
• Tami Pilot-Matias,
• Jens Kort,
• Federico Mensa

Affiliations

Fred Poordad

Texas Liver Institute, University of Texas Health Science Center, San Antonio, USA

Stanislas Pol

Groupe Hospitalier Cochin-Saint Vincent De Paul, Paris, France

Armen Asatryan

AbbVie Inc, North Chicago, IL, USA

Maria Buti

Vall d’Hebron University Hospital, Barcelona, Spain

David Shaw

Royal Adelaide Hospital, Australia

Christophe Hézode

Hôpital Henri Mondor, Université Paris-Est, Créteil, France

Franco Felizarta

Private Practice, Bakersfield, California, USA

Robert W. Reindollar

Piedmont Healthcare/Carolinas Center for Liver Disease, Statesville, North Carolina, USA

Stuart C. Gordon

Henry Ford Health System, Detroit, Michigan, USA

Stephen Pianko

Caulfield Endoscopy, Caulfield South, Victoria, Australia

Michael W. Fried

University of North Carolina, Chapel Hill, USA

David E. Bernstein

North Shore University Hospital, Manhasset, New York, USA

Joel Gallant

Southwest CARE Center, Santa Fe, New Mexico, USA

Chih-Wei Lin

AbbVie Inc, North Chicago, IL, USA

Yang Lei

AbbVie Inc, North Chicago, IL, USA

Teresa I. Ng

AbbVie Inc, North Chicago, IL, USA

Tami Pilot-Matias

AbbVie Inc, North Chicago, IL, USA

Jens Kort

AbbVie Inc, North Chicago, IL, USA

Federico Mensa

AbbVie Inc, North Chicago, IL, USA